Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Three thrombopoietin receptor agonists in childhood immune thrombocytopenia
ChiCTR2500095156Phase 4Recruiting
- Sponsor
- Fuyang People's Hospital
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of hetrombopag, avatrombopag and eltrombopag in immune thrombocytopenia (ITP) (3 arms), sponsored by Fuyang People's Hospital. Primary endpoint: Overall response rate after 8 weeks of drug treatment. Started Jan 2025; status: recruiting.
02
Drugs
hetrombopagavatrombopageltrombopag
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on ChiCTR2500095156.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500095156.